Cargando…

Arsenic Trioxide and Venetoclax Synergize against AML Progenitors by ROS Induction and Inhibition of Nrf2 Activation

Venetoclax (VEN) in combination with hypomethylating agents induces disease remission in patients with de novo AML, however, most patients eventually relapse. AML relapse is attributed to the persistence of drug-resistant leukemia stem cells (LSCs). LSCs need to maintain low intracellular levels of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hoang, Dinh Hoa, Buettner, Ralf, Valerio, Melissa, Ghoda, Lucy, Zhang, Bin, Kuo, Ya-Huei, Rosen, Steven T., Burnett, John, Marcucci, Guido, Pullarkat, Vinod, Nguyen, Le Xuan Truong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9223383/ https://www.ncbi.nlm.nih.gov/pubmed/35743010 http://dx.doi.org/10.3390/ijms23126568

Ejemplares similares

Synergy of Venetoclax and 8-Chloro-Adenosine in AML: The Interplay of rRNA Inhibition and Fatty Acid Metabolism
por: Hoang, Dinh Hoa, et al.
Publicado: (2022)

Targeting the metabolic vulnerability of acute myeloid leukemia blasts with a combination of venetoclax and 8-chloro-adenosine
por: Buettner, Ralf, et al.
Publicado: (2021)

The Addition of Arsenic Trioxide to Low Dose Ara-C in Older Patients with AML Does Not Improve Outcome
por: Burnett, Alan K, et al.
Publicado: (2011)

Venetoclax-containing regimens in acute myeloid leukemia
por: Aldoss, Ibrahim, et al.
Publicado: (2021)

Olaparib synergizes with arsenic trioxide by promoting apoptosis and ferroptosis in platinum-resistant ovarian cancer
por: Tang, Sangsang, et al.
Publicado: (2022)

P572: REAL-WORLD MANAGEMENT AND OUTCOMES FOR NEWLY DIAGNOSED AML PATIENTS INITIATING VENETOCLAX AND HYPOMETHYLATING AGENTS IN US COMMUNITY PRACTICE
por: Wang, Yuexi, et al.
Publicado: (2023)

Arsenic trioxide synergistically promotes the antileukaemic activity of venetoclax by downregulating Mcl-1 in acute myeloid leukaemia cells
por: Cho, Hyunsoo, et al.
Publicado: (2021)

Eriodictyol attenuates arsenic trioxide-induced liver injury by activation of Nrf2
por: Xie, Guanghong, et al.
Publicado: (2017)

Inhibition of early T cell cytokine production by arsenic trioxide occurs independently of Nrf2
por: VanDenBerg, Kelly R., et al.
Publicado: (2017)

Review of Venetoclax in CLL, AML and Multiple Myeloma
por: Lasica, Masa, et al.
Publicado: (2021)

EIF4A inhibition targets bioenergetic homeostasis in AML MOLM-14 cells in vitro and in vivo and synergizes with cytarabine and venetoclax
por: Fooks, Katie, et al.
Publicado: (2022)

Allosteric SHP2 inhibition increases apoptotic dependency on BCL2 and synergizes with venetoclax in FLT3- and KIT-mutant AML
por: Popescu, Bogdan, et al.
Publicado: (2023)

Clearance of bone marrow mast cells after hypomethylating agent and venetoclax for systemic mastocytosis associated with myeloid neoplasia
por: Pourhassan, Hoda, et al.
Publicado: (2022)

Retinoic acid synergizes ATO-mediated cytotoxicity by precluding Nrf2 activity in AML cells
por: Valenzuela, M, et al.
Publicado: (2014)

Augmenting Venetoclax Activity Through Signal Transduction in AML
por: Bouligny, Ian Michael, et al.
Publicado: (2023)

Evidences of Protective Potentials of Microdoses of Ultra-High Diluted Arsenic Trioxide in Mice Receiving Repeated Injections of Arsenic Trioxide
por: Banerjee, Pathikrit, et al.
Publicado: (2011)

MRD in Venetoclax-Based Treatment for AML: Does it Really Matter?
por: Bernardi, Massimo, et al.
Publicado: (2022)

In silico mechanisms of arsenic trioxide-induced cardiotoxicity
por: Li, Yacong, et al.
Publicado: (2022)

Arsenic trioxide as an inducer of immunogenic cell death
por: Kepp, Oliver, et al.
Publicado: (2023)

Immunological consequences of arsenic trioxide-induced necrosis
por: Gavali, Shubhangi, et al.
Publicado: (2023)

Acute myeloid leukemia in an 86-year-old man with AML1/ETO treated with Homoharringtonine and Arsenic Trioxide: A case report
por: He, Zhipeng, et al.
Publicado: (2019)

Retracted: Evidences of Protective Potentials of Microdoses of Ultra-High Diluted Arsenic Trioxide in Mice Receiving Repeated Injections of Arsenic Trioxide
por: Medicine, Evidence-Based Complementary and Alternative
Publicado: (2021)

miR-155 mediates arsenic trioxide resistance by activating Nrf2 and suppressing apoptosis in lung cancer cells
por: Gu, Shiyan, et al.
Publicado: (2017)

Metformin and arsenic trioxide synergize to trigger Parkin/pink1-dependent mitophagic cell death in human cervical cancer HeLa cells
por: Chen, Jing, et al.
Publicado: (2021)

Oxidative stress induced by the chemotherapeutic agent arsenic trioxide
por: Varghese, Mathews V., et al.
Publicado: (2013)

Arsenic Trioxide Sensitizes Glioblastoma to a Myc Inhibitor
por: Yoshimura, Yayoi, et al.
Publicado: (2015)

A Review of Arsenic Trioxide and Acute Promyelocytic Leukemia
por: Alimoghaddam, Kamran
Publicado: (2014)

Modulation of Cellular Response to Arsenic Trioxide Toxicity by Resveratrol
por: Mondal, Bodhisattwa, et al.
Publicado: (2018)

On arsenic trioxide in the clinical treatment of acute promyelocytic leukemia
por: Zhang, Peng
Publicado: (2017)

Effects of arsenic trioxide on the expression of ezrin in hepatocellular carcinoma
por: Lu, Wei, et al.
Publicado: (2017)

Effect of arsenic trioxide on cervical cancer and its mechanisms
por: Zhang, Liping, et al.
Publicado: (2020)

QT Independent Ventricular Tachycardia Induced by Arsenic Trioxide
por: Zeitjian, Vicken, et al.
Publicado: (2019)

Arsenic trioxide induces macrophage autophagy and atheroprotection by regulating ROS-dependent TFEB nuclear translocation and AKT/mTOR pathway
por: Fang, Shaohong, et al.
Publicado: (2021)

Based on Activation of p62-Keap1-Nrf2 Pathway, Hesperidin Protects Arsenic-Trioxide-Induced Cardiotoxicity in Mice
por: Jia, Yuxin, et al.
Publicado: (2021)

Arsenic speciation in saliva of acute promyelocytic leukemia patients undergoing arsenic trioxide treatment
por: Chen, Baowei, et al.
Publicado: (2013)

Case report of combination therapy with Azacytidine, Enasidenib and Venetoclax in primary refractory AML
por: Jasra, Sakshi, et al.
Publicado: (2021)

FOXM1-AKT Positive Regulation Loop Provides Venetoclax Resistance in AML
por: Chesnokov, Mikhail S, et al.
Publicado: (2021)

Lymphocyte Exhaustion in AML Patients and Impacts of HMA/Venetoclax or Intensive Chemotherapy on Their Biology
por: Zhigarev, Dmitry, et al.
Publicado: (2022)

P555: OLUTASIDENIB IN POST-VENETOCLAX PATIENTS WITH MUTANT IDH1 AML
por: Cortes, Jorge, et al.
Publicado: (2023)

Gestational Arsenic Trioxide Exposure Acts as a Developing Neuroendocrine-Disruptor by Downregulating Nrf2/PPARγ and Upregulating Caspase-3/NF-ĸB/Cox2/BAX/iNOS/ROS
por: Ahmed, R. G., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_mu5qbhvpumtl533gr7mvcs0qmf